Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Lu et.al. | ||||||||||||
Title | Abstract 2799: BAY 1082439, a highly selective and balanced PI3Kalpha/beta inhibitor demonstrated potent activity in tumors with activated PI3Kalpha and loss-of-function of PTEN | ||||||||||||
|
|||||||||||||
URL | http://cancerres.aacrjournals.org/content/72/8_Supplement/2799.short | ||||||||||||
Abstract Text | doi: 10.1158/1538-7445.AM2012-2799 Cancer Res April 15, 2012 72; 2799 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PIK3CA mutant | Advanced Solid Tumor | sensitive | BAY1082439 | Preclinical | Actionable | In a preclinical study, BAY1082439 induced regression in xenograft models of advanced solid tumors with PIK3CA mutations (Cancer Res April 15, 2012 72; 2799). | detail... |